Marizyme, Inc. is a biotechnology company which engages in the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. It offers DuraGraft, a one-time intraoperative vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure, and Krillase, a patented protease-based therapeutic. The company was founded on March 20, 2007 and is headquartered in Jupiter, FL.
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data